Cargando…
Etoposide-based therapy for severe forms of COVID-19
The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between modera...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207128/ https://www.ncbi.nlm.nih.gov/pubmed/32416415 http://dx.doi.org/10.1016/j.mehy.2020.109826 |
_version_ | 1783530544600973312 |
---|---|
author | Hamizi, Kamel Aouidane, Souhila Belaaloui, Ghania |
author_facet | Hamizi, Kamel Aouidane, Souhila Belaaloui, Ghania |
author_sort | Hamizi, Kamel |
collection | PubMed |
description | The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19. |
format | Online Article Text |
id | pubmed-7207128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72071282020-05-11 Etoposide-based therapy for severe forms of COVID-19 Hamizi, Kamel Aouidane, Souhila Belaaloui, Ghania Med Hypotheses Article The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19. Elsevier Ltd. 2020-09 2020-05-08 /pmc/articles/PMC7207128/ /pubmed/32416415 http://dx.doi.org/10.1016/j.mehy.2020.109826 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Hamizi, Kamel Aouidane, Souhila Belaaloui, Ghania Etoposide-based therapy for severe forms of COVID-19 |
title | Etoposide-based therapy for severe forms of COVID-19 |
title_full | Etoposide-based therapy for severe forms of COVID-19 |
title_fullStr | Etoposide-based therapy for severe forms of COVID-19 |
title_full_unstemmed | Etoposide-based therapy for severe forms of COVID-19 |
title_short | Etoposide-based therapy for severe forms of COVID-19 |
title_sort | etoposide-based therapy for severe forms of covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207128/ https://www.ncbi.nlm.nih.gov/pubmed/32416415 http://dx.doi.org/10.1016/j.mehy.2020.109826 |
work_keys_str_mv | AT hamizikamel etoposidebasedtherapyforsevereformsofcovid19 AT aouidanesouhila etoposidebasedtherapyforsevereformsofcovid19 AT belaalouighania etoposidebasedtherapyforsevereformsofcovid19 |